| [1] |
Chow YY, Chin KY. The role of inflammation in the pathogenesis of osteoarthritis[J/OL]. Mediators Inflamm, 2020, 2020: 8293921. DOI: 10.1155/2020/8293921.
|
| [2] |
Kovarik P, Ebner F, Sedlyarov V. Posttranscriptional regulation of cytokine expression[J]. Cytokine, 2017, 89: 21－26.
|
| [3] |
Malemud CJ. Matrix metalloproteinases and synovial joint pathology[J]. Prog Mol Biol Transl Sci, 2017, 148: 305－325.
|
| [4] |
van Dalen SCM, Blom AB, Slöetjes AW, et al. Interleukin-1 is not involved in synovial inflammation and cartilage destruction in collagenase-induced osteoarthritis[J]. Osteoarthr Cartil, 2017, 25(3): 385－396.
|
| [5] |
Attur M, Krasnokutsky S, Zhou H, et al. The combination of an inflammatory peripheral blood gene expression and imaging biomarkers enhance prediction of radiographic progression in knee osteoarthritis[J/OL]. Arthritis Res Ther, 2020, 22(1): 208. DOI: 10.1186/s13075-020-02298-6.
|
| [6] |
Wang C, Zeng L, Zhang T, et al. Tenuigenin prevents IL-1β-induced inflammation in human osteoarthritis chondrocytes by suppressing PI3K/AKT/NF-κB signaling pathway[J]. Inflammation, 2016, 39(2): 807－812.
|
| [7] |
Zhong L, Schivo S, Huang X, et al. Nitric oxide mediates crosstalk between interleukin 1β and WNT signaling in primary human chondrocytes by reducing DKK1 and FRZB expression[J/OL]. Int J Mol Sci, 2017, 18(11): 2491. DOI: 10.3390/ijms18112491.
|
| [8] |
Chen J, Wang C, Huang K, et al. Acacetin suppresses IL-1 β-induced expression of matrix metalloproteinases in chondrocytes and protects against osteoarthritis in a mouse model by inhibiting NF- κB signaling pathways[J/OL]. Biomed Res Int, 2020, 2020: 2328401. DOI: 10.1155/2020/2328401.
|
| [9] |
Philp AM, Davis ET, Jones SW. Developing anti-inflammatory therapeutics for patients with osteoarthritis[J]. Rheumatology (Oxford), 2017, 56(6): 869－881.
|
| [10] |
Mladenovic Z, Saurel AS, Berenbaum F, et al. Potential role of hyaluronic acid on bone in osteoarthritis: matrix metalloproteinases, aggrecanases, and RANKL expression are partially prevented by hyaluronic acid in interleukin 1-stimulated osteoblasts[J]. J Rheumatol, 2014, 41(5): 945－954.
|
| [11] |
Avenoso A, D'Ascola A, Scuruchi M, et al. Hyaluronan in the experimental injury of the cartilage: biochemical action and protective effects[J]. Inflamm Res, 2018, 67(1): 5－20.
|
| [12] |
Xue EX, Lin JP, Zhang Y, et al. Pterostilbene inhibits inflammation and ROS production in chondrocytes by activating Nrf2 pathway[J]. Oncotarget, 2017, 8(26): 41988－42000.
|
| [13] |
Jotanovic Z, Mihelic R, Sestan B, et al. Role of interleukin-1 inhibitors in osteoarthritis: an evidence-based review[J]. Drugs Aging, 2012, 29(5): 343－358.
|
| [14] |
Jenei-Lanzl Z, Meurer A, Zaucke F. Interleukin-1β signaling in osteoarthritis - chondrocytes in focus[J]. Cell Signal, 2019, 53: 212－223.
|
| [15] |
Nasi S, Ea HK, So A, et al. Revisiting the role of interleukin-1 pathway in osteoarthritis: interleukin-1α and-1β，and NLRP3 inflammasome are not involved in the pathological features of the murine menisectomy model of osteoarthritis[J/OL]. Front Pharmacol, 2017, 8: 282. DOI: 10.3389/fphar.2017.00282.
|
| [16] |
Ajrawat P, Dwyer T, Chahal J. Autologous interleukin 1 receptor antagonist blood-derived products for knee osteoarthritis: a systematic review[J]. Arthroscopy, 2019, 35(7): 2211－2221.
|
| [17] |
Li EQ, Zhang JL. Therapeutic effects of triptolide from Tripterygium wilfordii Hook. f. on interleukin-1-beta-induced osteoarthritis in rats[J/OL]. Eur J Pharmacol, 2020, 883: 173341. DOI: 10.1016/j.ejphar.2020.173341.
|
| [18] |
Ansari MY, Khan NM, Haqqi TM. A standardized extract of Butea monosperma (Lam.) flowers suppresses the IL-1β-induced expression of IL-6 and matrix-metalloproteases by activating autophagy in human osteoarthritis chondrocytes[J]. Biomed Pharmacother, 2017, 96: 198－207.
|
| [19] |
Attur M, Zhou H, Samuels J, et al. Interleukin 1 receptor antagonist (IL1RN) gene variants predict radiographic severity of knee osteoarthritis and risk of incident disease[J]. Ann Rheum Dis, 2020, 79(3): 400－407.
|
| [20] |
Nixon AJ, Grol MW, Lang HM, et al. Disease-modifying osteoarthritis treatment with interleukin-1 receptor antagonist gene therapy in small and large animal models[J]. Arthritis Rheumatol, 2018, 70(11): 1757－1768.
|
| [21] |
Watson Levings RS, Broome TA, Smith AD, et al. Gene therapy for osteoarthritis: pharmacokinetics of intra-articular self-complementary adeno-associated virus interleukin-1 receptor antagonist delivery in an equine model[J]. Hum Gene Ther Clin Dev, 2018, 29(2): 90－100.
|
| [22] |
Gabner S, Ertl R, Velde K, et al. Cytokine-induced interleukin-1 receptor antagonist protein expression in genetically engineered equine mesenchymal stem cells for osteoarthritis treatment[J/OL]. J Gene Med, 2018, 20(5): e3021. DOI: 10.1002/jgm.3021.
|
| [23] |
Nguyen HN, Noss EH, Mizoguchi F, et al. Autocrine loop involving IL-6 family member LIF, LIF receptor, and STAT4 drives sustained fibroblast production of inflammatory mediators[J]. Immunity, 2017, 46(2): 220－232.
|
| [24] |
Wiegertjes R, van de Loo FAJ, Blaney Davidson EN. A roadmap to target interleukin-6 in osteoarthritis[J]. Rheumatology (Oxford), 2020, 59(10): 2681－2694.
|
| [25] |
Sahu N, Viljoen HJ, Subramanian A. Continuous low-intensity ultrasound attenuates IL-6 and TNFα-induced catabolic effects and repairs chondral fissures in bovine osteochondral explants[J/OL]. BMC Musculoskelet Disord, 2019, 20(1): 193. DOI: 10.1186/s12891-019-2566-4.
|
| [26] |
Nasi S, So A, Combes C, et al. Interleukin-6 and chondrocyte mineralisation act in tandem to promote experimental osteoarthritis[J]. Ann Rheum Dis, 2016, 75(7): 1372－1379.
|
| [27] |
Qu XQ, Wang WJ, Tang SS, et al. Correlation between interleukin-6 expression in articular cartilage bone and osteoarthritis[J]. Genet Mol Res, 2015, 14(4): 14189－14195.
|
| [28] |
Wang T, He C. Pro-inflammatory cytokines: the link between obesity and osteoarthritis[J]. Cytokine Growth Factor Rev, 2018, 44: 38－50.
|
| [29] |
Ai Z, Ning X, Shou T, et al. Association of interleukin-6 promoter polymorphism with knee osteoarthritis: a meta-analysis[J]. Chin Med J (Engl), 2014, 127(13): 2492－2496.
|
| [30] |
Blumenfeld O, Williams FM, Valdes A, et al. Association of interleukin-6 gene polymorphisms with hand osteoarthritis and hand osteoporosis[J]. Cytokine, 2014, 69(1): 94－101.
|
| [31] |
Yang H, Zhou X, Xu D, et al. The IL-6 rs12700386 polymorphism is associated with an increased risk of developing osteoarthritis in the knee in the Chinese Han population: a case-control study[J/OL]. BMC Med Genet, 2020, 21(1): 199. DOI: 10.1186/s12881-020-01139-2.
|
| [32] |
Favero M, Belluzzi E, Trisolino G, et al. Inflammatory molecules produced by meniscus and synovium in early and end-stage osteoarthritis: a coculture study[J]. J Cell Physiol, 2019, 234(7): 11176－11187.
|
| [33] |
Pratama DGK, Suyasa IK, Astawa P, et al. High IL-6 level as a marker of lumbar osteoarthritis in patients older than 55 years with low back pain[J]. Orthop Res Rev, 2019, 11: 17－21.
|
| [34] |
Latourte A, Cherifi C, Maillet J, et al. Systemic inhibition of IL-6/Stat3 signalling protects against experimental osteoarthritis[J]. Ann Rheum Dis, 2017, 76(4): 748－755.
|
| [35] |
Wu X, Cao L, Li F, et al. Interleukin-6 from subchondral bone mesenchymal stem cells contributes to the pathological phenotypes of experimental osteoarthritis[J]. Am J Transl Res, 2018, 10(4): 1143－1154.
|
| [36] |
Ansari MY, Khan NM, Ahmad N, et al. Genetic inactivation of ZCCHC6 suppresses interleukin-6 expression and reduces the severity of experimental osteoarthritis in mice[J]. Arthritis Rheumatol, 2019, 71(4): 583－593.
|
| [37] |
Garbers C, Heink S, Korn T, et al. Interleukin-6: designing specific therapeutics for a complex cytokine[J]. Nat Rev Drug Discov, 2018, 17(6): 395－412.
|
| [38] |
Si Z, Zhou S, Shen Z, et al. lncRNA HAND2-AS1 is downregulated in osteoarthritis and regulates IL-6 expression in chondrocytes[J/OL]. J Orthop Surg Res, 2021, 16(1): 68. DOI: 10.1186/s13018-021-02216-9.
|
| [39] |
Monasterio G, Castillo F, Rojas L, et al. Th1/Th17/Th22 immune response and their association with joint pain, imagenological bone loss, RANKL expression and osteoclast activity in temporomandibular joint osteoarthritis: a preliminary report[J]. J Oral Rehabil, 2018, 45(8): 589－597.
|
| [40] |
Sinkeviciute D, Aspberg A, He Y, et al. Characterization of the interleukin-17 effect on articular cartilage in a translational model: an explorative study[J/OL]. BMC Rheumatol, 2020, 4: 30. DOI: 10.1186/s41927-020-00122-x.
|
| [41] |
Na HS, Park JS, Cho KH, et al. Interleukin-1-interleukin-17 signaling axis induces cartilage destruction and promotes experimental osteoarthritis[J/OL]. Front Immunol, 2020, 11: 730. DOI: 10.3389/fimmu.2020.00730.
|
| [42] |
Bai Y, Gao S, Liu Y, et al. Correlation between Interleukin-17 gene polymorphism and osteoarthritis susceptibility in Han Chinese population[J/OL]. BMC Med Genet, 2019, 20(1): 20. DOI: 10.1186/s12881-018-0736-0.
|
| [43] |
Wan L, Zhao Q, Niu G, et al. Plasma miR-136 can be used to screen patients with knee osteoarthritis from healthy controls by targeting IL-17[J]. Exp Ther Med, 2018, 16(4): 3419－3424.
|
| [44] |
Huang T, Wang J, Zhou Y, et al. LncRNA CASC2 is up-regulated in osteoarthritis and participates in the regulation of IL-17 expression and chondrocyte proliferation and apoptosis[J/OL]. Biosci Rep, 2019, 39(5): BSR20182454. DOI: 10.1042/BSR20182454.
|
| [45] |
Koh SM, Chan CK, Teo SH, et al. Elevated plasma and synovial fluid interleukin-8 and interleukin-18 may be associated with the pathogenesis of knee osteoarthritis[J]. Knee, 2020, 27(1): 26－35.
|
| [46] |
Bao J, Chen Z, Xu L, et al. Rapamycin protects chondrocytes against IL-18-induced apoptosis and ameliorates rat osteoarthritis[J]. Aging (Albany NY), 2020, 12(6): 5152－5167.
|
| [47] |
Xue JF, Shi ZM, Zou J, et al. Inhibition of PI3K/AKT/mTOR signaling pathway promotes autophagy of articular chondrocytes and attenuates inflammatory response in rats with osteoarthritis[J]. Biomedecine Pharmacother, 2017, 89: 1252－1261.
|
| [48] |
Waly NE, Refaiy A, Aborehab NM. IL-10 and TGF-β：roles in chondroprotective effects of Glucosamine in experimental Osteoarthritis？[J]. Pathophysiology, 2017, 24(1): 45－49.
|
| [49] |
Schwarz S, Mrosewski I, Silawal S, et al. The interrelation of osteoarthritis and diabetes mellitus: considering the potential role of interleukin-10 and in vitro models for further analysis[J]. Inflamm Res, 2018, 67(4): 285－300.
|
| [50] |
Li S, Wan J, Anderson W, et al. Downregulation of IL-10 secretion by Treg cells in osteoarthritis is associated with a reduction in Tim-3 expression[J]. Biomedecine Pharmacother, 2016, 79: 159－165.
|
| [51] |
Suyasa IK, Kawiyana IK, Bakta IM, et al. Interleukin-6 and ratio of plasma interleukin-6/interleukin-10 as risk factors of symptomatic lumbar osteoarthritis[J]. World J Orthop, 2017, 8(2): 149－155.
|
| [52] |
Assis L, Tim C, Magri A, et al. Interleukin-10 and collagen type II immunoexpression are modulated by photobiomodulation associated to aerobic and aquatic exercises in an experimental model of osteoarthritis[J]. Lasers Med Sci, 2018, 33(9): 1875－1882.
|
| [53] |
Kwon JY, Lee SH, Na HS, et al. Kartogenin inhibits pain behavior, chondrocyte inflammation, and attenuates osteoarthritis progression in mice through induction of IL-10[J/OL]. Sci Rep, 2018, 8(1): 13832. DOI: 10.1038/s41598-018-32206-7.
|
| [54] |
Broeren MG, de Vries M, Bennink MB, et al. Suppression of the inflammatory response by disease-inducible interleukin-10 gene therapy in a three-dimensional micromass model of the human synovial membrane[J/OL]. Arthritis Res Ther, 2016, 18: 186. DOI: 10.1186/s13075-016-1083-1.
|
| [55] |
Watkins LR, Chavez RA, Landry R, et al. Targeted interleukin-10 plasmid DNA therapy in the treatment of osteoarthritis: Toxicology and pain efficacy assessments[J]. Brain Behav Immun, 2020, 90: 155－166.
|
| [56] |
van Geffen EW, van Caam APM, Vitters EL, et al. Interleukin-37 protects stem cell-based cartilage formation in an inflammatory osteoarthritis-like microenvironment[J]. Tissue Eng Part A, 2019, 25(15－16): 1155－1166.
|
| [57] |
Luo P, Feng C, Jiang C, et al. IL-37b alleviates inflammation in the temporomandibular joint cartilage via IL-1R8 pathway[J/OL]. Cell Prolif, 2019, 52(6): e12692. DOI: 10.1111/cpr.12692.
|
| [58] |
Ding L, Hong X, Sun B, et al. IL-37 is associated with osteoarthritis disease activity and suppresses proinflammatory cytokines production in synovial cells[J/OL]. Sci Rep, 2017, 7(1): 11601. DOI: 10.1038/s41598-017-11397-5.
|
| [59] |
van Geffen EW, van Caam APM, Schreurs W, et al. IL-37 diminishes proteoglycan loss in human OA cartilage: donor-specific link between IL－37 and MMP-3[J]. Osteoarthritis Cartilage, 2019, 27(1): 148－157.
|